-
최근 눈영양제 아이락루테인으로 건강기능식품 시장을 이끌고 있는 한국알리코팜이 천연물 치료제 개발에 나선다.한국알리코팜은 지난 19일 경기바이오센터에서 (재)경기의약연구센터와 천연물 성분의 항알러지 신약 개발 협약을 위한 양해각서를 체결했다고 24일 밝혔다.양 측은 이전까지도 항알러지 치료제를 공동개발해왔는데 최근 연구성과가 보건복지가족부의 정책과제로 선정되면서 본격적인 협약을 맺고 개발에 나서기로 한 것이다.이날 한국알리코팜 이항구 대표이사와 경기의약연구센터 지옥표 센터장은 "항알러지에 효과가 입증된 천연물 제제가 없는 만큼 국민 보건향상을 위해 향후 2년 이내 제품화하겠다"며 개발 의욕을 밝혔다.
제약바이오
박상준 기자
2009.08.25 00:00
-
In a letter to Allergan, the FDA has said that a medical journal article from the company is a complete misrepresentation of the results of a study of its acne treatment Aczone [dapsone] and that risk factors are omitted. The FDA expects a written response from the company by August 28 citing an ad that exaggerates the benefit of the drug but according to a spokeswoman for Allergan the ad in quest
제약단신
메디칼라이터팀
2009.08.25 00:00
-
In a law suit over the sleep-disorder drug Provigil, CVS and Rite Aid claim that Cephalon signed four patent settlements with generic drugmakers totaling more than $200 million so they wouldn"t begin sales until 2012. They claim that Cephalon is actively working against the release of the generic Provigil which could have been available as early as January 2006. The drug currently has FDA approva
제약단신
메디칼라이터팀
2009.08.25 00:00
-
The oral solution, Sabril [vigabatrin], has been approved by the FDA for children between the ages of one month and two years and is the first drug to treat infantile spasms which is a rare disorder leading to hundreds of seizures in children under a year old. During testing scientists believed that the disorder was caused by a deficit of gamma-amino-butyric acid (GABA) in the brain so developed t
제약단신
메디칼라이터팀
2009.08.25 00:00
-
In a deal expected to close in the fourth quarter, biotech drugmaker MediciNova Inc. will buy its smaller rival for about $37 million. Both companies are running clinical trials for the drug candidate called ibudilast. Avigen is testing the drug as a treatment for chronic nerve pain, addiction to opioids and methamphetamine, and opioid withdrawal, while MediciNova is testing it for use in multiple
제약단신
메디칼라이터팀
2009.08.25 00:00
-
Warner Chilcott will buy Procter & Gamble"s prescription drug business for about $3 billion in a deal financed by 6 banks including Bank of America and JPMorgan Chase. According to data from Dealogic this will be the fourth-largest leveraged loan in the US this year. The deal comes after many months of searching by P&G whose drugs treat bone loss, digestive disorders, and women"s health and will
제약단신
메디칼라이터팀
2009.08.25 00:00
-
서비스 활성화는 아직…정부시범사업 참여로 경쟁력 키워야 "U-Healthcare 서비스가 본격적으로 도입되고, 의료 소비 행태가 변화하면서 IT업계에서도 의료 시장이 새로운 블루오션으로 부상하게 될 것이다. 의료산업과 관계된 모든 참여자들은 상황 변화에 대응하지 않을 수 없게 될 것이며, 의사들의 역할도 대단히 중요할 것이다." LG경제연구원은 최근 "U-Healthcare가 다가온다"라는 보고서를 통해 "헬스케어 산업에 있거나, 이 산업을 통해 기회를 찾고자 하는 기업들은 U-Healthcare 측면에서 업계의 변화를 예의주시해야 한다"며 "산업화를 위한 대안을 찾기 위해 다양한 노력을 해야 한다"고 제언했다. 우선 현재로서는 개인의 비용에 기반한 U-Healthcare 서비스가 활성화되는 데에는
의료기기
임솔 기자
2009.08.24 00:00
-
최근 신종플루 확산에 따라 백신에 대한 국민의 관심이 높아지고 있는 가운데 식품의약품안전청이 ‘백신 안전사용을 위한 핸드북’을 발간했다.이 핸드북에는 국내 백신의 종류별 국내 허가 현황, 취급상 주의사항, 접종시 주의사항 등 관련 정보를 총 망라되어 있다.식약청은 핸드북 활용을 통해 백신 취급자들의 백신 안전 사용에 도움이 되는 한편, 유해사례 등 백신의 안전성 보고도 활성화될 수 있을 것으로 기대된다고 밝혔다.핸드북은 백신을 주로 취급하는 전국 보건소와 의사협회 등 관련 협회에 배포할 예정이며, 식약청 홈페이지 간행물 코너에서 다운로드 받을 수 있다.
제약바이오
박상준 기자
2009.08.24 00:00
-
According to WHO"s Western Pacific director, Shin Young-soo, there will be a period of global spread of the virus, and countries may see swine flu cases double every three to four days for several months until peak transmission is reached. Speaking at a symposium of health officials and experts in Beijing, he urged governments to get ready for a quick response to prevent unnecessary deaths from t
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Speaking at a three-day symposium on influenza in the Asia-Pacific region, World Health Organization chief Margaret Chan, has said that a second or even a third wave of swine flu cases was a possibility. She said that limited vaccine supplies could create extremely difficult decisions for governments and that they should be gathering information on priority groups in the event of another round of
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Two small research firms, Legitscript.com and KnujOn.com say that during a three-month period in the spring and early summer of 2009, Yahoo routinely accepted ads from dozens of online pharmacies that dispensed drugs without a valid prescription. Their researchers were able purchase a wide variety of prescription drugs from around a dozen online pharmacy sites that advertised on Yahoo without disc
제약단신
메디칼라이터팀
2009.08.22 00:00
-
The FDA has issued warnings to eight companies who do not have federal permission to market pain relief ointments containing ibuprofen and has given them 15 business days to respond. According to Deborah M. Autor, director of the Office of Compliance at the FDA"s Center for Drug Evaluation and Research, the products have not been evaluated for safety, effectiveness and potential side-effects. The
제약단신
메디칼라이터팀
2009.08.22 00:00
-
An industry funded study has shown that patients who received preventive treatment for venous thromboembolic disease (VTE) with the anticoagulant enoxaparin, a low molecular weight heparin sold as Lovenox and Clexane, incurred lower hospital costs than if they were treated with unfractionated heparin (UFH). According to data appearing in the Journal of Thrombosis and Thrombolysis, hospital costs o
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Hiberix, a vaccine that helps prevent the bacterial infection Haemophilus influenzae type b (Hib) which can cause meningitis, was approved by the FDA as the fourth booster dose for children 15 months to four years old. The GlaxoSmithKline PLC vaccine was given accelerated approval due to a shortage of the vaccine after Merck & Co. Inc. withdrew 1.2 million doses in 2007 because of suspected contam
제약단신
메디칼라이터팀
2009.08.22 00:00
-
A federal judge in New Jersey has ruled to uphold Merck & Co."s patent of Singulair. An Israeli company wants to sell a generic version of Merck"s top-selling drug and Teva Pharmaceuticals USA sought FDA approval to sell generic versions of three doses. The federal judge issued an injunction preventing generic versions to enter the US market until the patent expires in August 2012. The patent co
제약단신
메디칼라이터팀
2009.08.21 00:00
-
For a study 8,000 postmenopausal women with hormone receptor-positive breast cancer were randomly assigned tamoxifen or Novartis AG"s Femara [letrozole] for five years and some of the women were also assigned to switch drugs after two years. Strong evidence was found that letrozole prolongs overall survival compared with tamoxifen. Over six years cancer-free survival was equal in women who had t
제약단신
메디칼라이터팀
2009.08.21 00:00
-
Pfizer Inc. and the information technology company, Private Access intend to create a website where patients can find out about clinical trials, and where physicians, researchers, and drug companies can look for test subjects. Patients will be able to use privacy options so that selected personal information is only available to researchers on specific illnesses that are of interest to them and ac
제약단신
메디칼라이터팀
2009.08.21 00:00
-
A study concludes that Iressa [gefitinib] can slow the deadly nonsmall-cell lung cancer (NSCLC) better than standard chemotherapy in patients who have the epidermal growth factor receptor (EGFR) gene mutation. According to lead investigator Tony S. Mok, MD, from the Chinese University of Hong Kong, the presence of an EGFR mutation was a robust predictor of improved progression-free survival with
제약단신
메디칼라이터팀
2009.08.21 00:00
-
Sanofi-Aventis SA"s patent on the blood-thinner Plavix [clopidogrel bisulfate] will be reconsidered by the US Patent and Trademark Office (USPTO) to determine whether it should have been issued. Apotex submitted the request at the USPTO after an appeals court upheld the patent in December preventing the company from selling a copy of the drug until November 2011. Bristol-Myers and Sanofi are see
제약단신
메디칼라이터팀
2009.08.20 00:00
-
Durect Corp. has granted Taiwan-based Orient Pharma Co. the rights to the attention-deficit hyperactivity disorder drug candidate, called Oradur-AD/HD in selected Asian and South Pacific nations. Durect will retain the rights to the drug, which it hopes will be a once-daily, tamper-resistant treatment for AD/HD, in North America, Europe, Japan, and select other countries.
제약단신
메디칼라이터팀
2009.08.20 00:00